TBP.V - Tetra Bio-Pharma Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.2350
+0.0250 (+11.90%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.2100
Open0.2200
Bid0.2300 x 0
Ask0.2350 x 0
Day's Range0.2200 - 0.2450
52 Week Range0.1700 - 0.6900
Volume2,981,542
Avg. Volume953,678
Market Cap57.921M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.0740
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Does The Tetra Bio-Pharma Inc. (CVE:TBP) Share Price Tend To Follow The Market?
    Simply Wall St.

    Does The Tetra Bio-Pharma Inc. (CVE:TBP) Share Price Tend To Follow The Market?

    If you own shares in Tetra Bio-Pharma Inc. (CVE:TBP) then it's worth thinking about how it contributes to the...

  • CNW Group

    IIROC Trading Resumption - TBP

    VANCOUVER , May 15, 2020 /CNW/ - Trading resumes in: Company: Tetra Bio-Pharma Inc. TSX-Venture Symbol: TBP (All Issues) Resumption (ET): 11:30 AM IIROC can make a decision to impose a temporary suspension ...

  • ACCESSWIRE

    Two Quebec Companies Joined Forces to Make Healthcare Mask for our "Guardian Angels"

    OTTAWA, ON / ACCESSWIRE / May 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development and ARTOFIX a Quebec City based high performance mask manufacturer are pleased to announce that Tetra has secured a Medical Device Establishment License (MDEL) for a Class 1 medical device manufacturer for Artofix. This will allow Artofix to expedite the launch of a mask with the same minimum filtration efficiencyof 95% as the N-95 masks, and will meet the safety needs of healthcare professionals and other essential workers. Like N-95 masks, they will be adjustable and comfortable, both features that are essential for healthcare professionals.

  • GlobeNewswire

    Tetra Bio-Pharma Announces Overnight Marketed Offering

    Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it has commenced an overnight marketed public offering (the “Offering”) of units (the “Units”) of the Company. Each Unit is offered at a price of $0.26 per Unit (the “Issue Price”) with each Unit consisting of one common share in the capital of Tetra (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $0.32 for a period of 36 months from the closing date of the Offering.

  • CNW Group

    IIROC Trading Halt - TBP

    IIROC Trading Halt - TBP

  • ACCESSWIRE

    Tetra Announces Resignation of President

    OTTAWA, ON / ACCESSWIRE / May 13, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, announces that its Board of Directors has accepted the resignation of Mr. Sylvain Chretien as President of the Company. In light of Mr. Chretien's resignation, the Board has decided not to appoint another president at this time. Due to the COVID-19 pandemic and the Company's reduced corporate activity in business development and promotion the role of Mr. Chretien as President was no longer determined to be essential at this time.

  • ACCESSWIRE

    Tetra Bio-Pharma Provides Update on PPP003 Inflammatory Cytokine Reduction Drug Program

    OTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that its Chief Operating Officer Steeve Néron participated in an interview on Saturday to discuss the Company's development of a drug program to treat certain symptoms of COVID-19. As mentioned in previous press releases, the Company is developing its already existing initial PPP003 program as a potential intravenous drug as well as a second PPP003 indication for Cytokine Release Syndrome ("CRS") to treat certain symptoms of COVID-19. Management believes that under an accelerated timeline, a potential drug for CRS could be ready for conditional approval by Health Canada during the third quarter of 2021.

  • ACCESSWIRE

    Tetra Bio-Pharma Obtains Health Canada Approval for Renewal of its Veterinary Clinical Study

    OTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V)(TBPMF) , a leader in cannabinoid-derived drug discovery and development, is pleased to announce that its pilot clinical study to evaluate the tolerability and potential efficacy of its PPP003 ophthalmic drug in the treatment of indolent corneal ulcers in companion animals has received its authorization by the Veterinary Drugs Directorate (VDD), Health Canada to continue. The VDD granted the renewal of the Experimental Studies Certificate (ESC) to the veterinary ophthalmologists that will be performing the clinical study for Panag Pharma (PANAG).

  • ACCESSWIRE

    Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program

    OTTAWA, ON / ACCESSWIRE / May 6, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V)(TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has now completed the modifications to the nonclinical safety program of PPP003 to ensure the launch of a Phase 1 trial in healthy volunteers later this year and subsequently be able to initiate a Phase 2 trial in patients with COVID-19 immediately after. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. As with any new drug candidate, PPP003 has not been shown to be safe or effective in the prevention or treatment of inflammatory cytokine conditions.

  • ACCESSWIRE

    Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome

    OTTAWA, ON / ACCESSWIRE / April 27, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V)(TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it is adding a new indication in the development of PPP003. Panag Pharma's (Panag), a subsidiary of Tetra, PPP003 is a synthetic cannabinoid drug that selectively acts at the type 2 cannabinoid receptor (CB2R).

  • Newsfile

    Tetra Bio-Pharma Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and Cannabinoid-Based Topical Cream with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - April 22, 2020) - The Stock Day Podcast welcomed Tetra Bio-Pharma (OTCQB: TBPMF) ("the Company"), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. CEO of the Company, Dr. Guy Chamberland, joined Stock Day host Everett Jolly. Jolly began the interview by asking about ...

  • ACCESSWIRE

    Tetra Expands on its Orphan Drug Development Program and Management Update

    OTTAWA / ACCESSWIRE / April 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V)(TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce its Orphan Drug development strategy and provide a management update. Tetra is focused on generating intellectual property including use, manufacturing, and innovative molecule protection.

  • ACCESSWIRE

    Tetra Receives its 4th FDA Orphan Drug Designation

    OTTAWA / ACCESSWIRE / April 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V);(TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its cannabinoid PPP004 (THC-CBD) in the treatment of epidermolysis bullosa. Epidermolysis bullosa is a group of rare diseases that cause fragile, blistering skin and is associated with significant pain and reduced quality of life.

  • ACCESSWIRE

    Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program

    OTTAWA / ACCESSWIRE / April 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its synthetic cannabinoid PPP003 (HU308) in the prevention of proliferative vitreoretinopathy. Proliferative vitreoretinopathy (PVR) is a vision-threatening condition that develops in approximately 10% of patients who undergo reparative primary retinal detachment surgery and in about 50% of patients with open globe injury.

  • ACCESSWIRE

    Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License

    OTTAWA / ACCESSWIRE / April 14, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Dr. Sue Sisley's Scottsdale Research Institute received the renewal of its Schedule 1 license from the US Drug Enforcement Agency (DEA). The receipt of the DEA Schedule 1 license is a significant milestone in the advancement of the Plenitude trial and ultimately getting QIXLEEF™ into the market.

  • Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions
    CNW Group

    Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions

    OTTAWA, April 8, 2020 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP.V - News) (OTCQB:TBPMF - News), a leader in cannabinoid-derived drug discovery and development has joined the battle to fight the novel COVID-19 virus. The Company will mobilize its expertise in regulatory affairs and quality assurance to support Canadian businesses seeking Health Canada approval for specific products used to mitigate the ongoing COVID-19 pandemic. This week Tetra Bio-Pharma submitted a Drug Information Number (DIN) application to Health Canada on behalf of a Canadian company ready to produce a hospital, institutional grade hard surface disinfectant.

  • GlobeNewswire

    Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011

    Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the U.S. Food & Drug Administration ("FDA") has granted the Company’s request for a Type B meeting related to its proposed clinical program and overall premarketing requirements for the Company’s product HCC011 with Orphan Drug Designation. This meeting has been scheduled for May 29, 2020.

  • GlobeNewswire

    Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF

    Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to determine the levels of cannabinoid metabolites (e.g., 7-COOH-CBD), cannabinoid precursors (e.g., CBGA) and minor cannabinoids (e.g., CBN) in the plasma of humans.

  • CNW Group

    Tetra Bio Pharma Announces Filing of Final Base Shelf Prospectus for up to $50 Million of Securities

    OTTAWA , April 1, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF) announced today that it has filed a final short form base shelf prospectus with the securities commissions in each of the provinces of Canada . The base shelf prospectus will allow Tetra and certain of its security holders to qualify the distribution by way of prospectus of up to $50,000,000 of common shares, warrants, units, debt securities, subscription receipts, or any combination thereof, from time to time during the 25-month period that the shelf prospectus is effective.

  • GlobeNewswire

    Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF), announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 ("Restated MD&A"), which is available on SEDAR under the Corporation's profile. The board of directors of the Corporation, based on the recommendation of the audit committee in consultation with the management of the Corporation, has determined that the Corporation’s previously filed management’s discussion and analysis for the for the financial year ended November 30, 2019 ("Previously Filed MD&A") needed to be restated to incorporate disclosure on the COVID-19 pandemic and its impact on the general business of Tetra. The Previously Filed MD&A was originally filed by the Corporation on SEDAR on March 25, 2020.

  • GlobeNewswire

    Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial

    Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the results of a survey conducted among US and Canadian patients and physicians which validated the primary endpoint of the SERENITY© pivotal trial. Fifty to 80% of cancer patients experience cachexia during their disease1 Cachexia is defined as “multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment”2.